Apr. 2, 2026
Massey Pioneers New Stage III Colon Cancer Therapy
VCU Massey Comprehensive Cancer Center plays vital role in phase III clinical trial establishing new standard of care.
Apr. 2, 2026
Orca Bio Announces FDA Review Extension for Orca-T Blood Cancer Treatment
New PDUFA target date of July 6, 2026 allows additional time for FDA review.
Apr. 2, 2026
NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Pressing issues in oncology, including rising cancer incidences in younger people, plus global opportunities for improving outcomes, were presented alongside cutting-edge research and clinical guidelines updates, during yearly event hosted by the National Comprehensive Cancer Network.
Apr. 2, 2026
Mayo Clinic Study Finds Robotic Bronchoscopy Safer, More Accurate for Lung Cancer Diagnosis
Researchers report high sensitivity and diagnostic yield for the minimally invasive procedure.
Apr. 2, 2026
New Study Finds Anti-Aging Supplements May Fuel Cancer
Researchers warn popular NAD+ boosters could undermine chemotherapy for cancer patients
Apr. 2, 2026
Tenpoint Therapeutics and PHIL Launch YUVEZZI Direct-to-Patient Program
New cash program aims to improve access to novel treatment for rare disease patients.
Apr. 2, 2026
Curanex Expands Drug Pipeline to Include Cancer Cachexia
New focus represents multi-billion-dollar market opportunity and evolution of company's therapeutics development
Apr. 2, 2026
EU Approves KEYTRUDA Plus Paclitaxel for Platinum-Resistant Ovarian Cancer
The regimen is the first and only PD-1 inhibitor-based treatment option for eligible patients in the EU.
Apr. 2, 2026
Seaport Therapeutics Announces Positive Proof of Concept Results
Biotech firm reports promising early-stage data for new treatment
Apr. 2, 2026
IMFINZI® and IMJUDO® Combo Improves Liver Cancer Outcomes
The drug combination demonstrated progression-free survival benefits in early-stage liver cancer patients.
Apr. 2, 2026
CanWell Pharma Announces FDA Clearance for New Cancer Drug
The biotech firm's dual-payload antibody-drug conjugate targets HER2 and is moving to clinical trials.
Apr. 2, 2026
EU Approves Keytruda Combo for Cervical Cancer Treatment
The new treatment regimen combines Keytruda, paclitaxel, and bevacizumab for adult patients.
Apr. 2, 2026
MiNK Therapeutics to Present New Data on iNKT Cell Therapy at ASGCT 2026
Presentation to highlight context-dependent activity of investigational agenT-797 in cancer and severe respiratory disease
Apr. 2, 2026
Context Therapeutics' CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
Designation highlights potential to address unmet need for patients with PROC
Apr. 2, 2026
Routine Blood Test Catches Early-Stage Cancer in Miami Man
37-year-old credits proactive health screening for life-saving diagnosis
Apr. 2, 2026
Voro Therapeutics to Present New Preclinical Data on PrimeBody™ Platform and VOR-101 at Upcoming Conferences
The biotechnology company will showcase the power of its tumor-activated biologics platform at AACR 2026 and AET Europe.
Apr. 2, 2026
New Research Targets MD2 to Curb Prostate Cancer Spread
Preclinical study shows MD2 inhibition reduces tumor growth in prostate cancer bone metastasis model
Apr. 2, 2026
Nuvation Bio Acquires Japan Rights to Safusidenib from Daiichi Sankyo
Agreement provides Nuvation Bio global development and commercialization rights for investigational IDH1 inhibitor
Apr. 2, 2026
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis
Over 65% of Patients Reported Reduced Pain and Itching with Zero Disruptions to EGFR Cancer Therapy
Apr. 2, 2026
Calidi Biotherapeutics to Present New Data on In Situ T-Cell Engagers at AACR 2026
The biotech company will showcase its RedTail virotherapy platform and a new TROP-2 targeting candidate at the cancer research conference.
